
Opioids in Australia THS Biarritz, France 2009

Assoc Prof Adrian Dunlop Newcastle, Australia

Australian opiate treatment system

✓ Methadone 1970s, buprenorphine 2001
 ✓ Buprenorphine-naloxone 2005
 ✓ Expanded to prevent HIV in IDU
 ✓ Relatively accessible
 ✓ Relatively inexpensive
 ✓ (~ €2400 pa, subsidised)

Number in methadone + buprenorphine treatment




Australian opiate treatment system

~41,000 patients in treatment rate ~ France ~195/100,000 population Age ~ 20-50 2/3 men, 1/3 women HIV < 1%, HCV 60-70% Indigenous 8%

Treatment system

Mix of public and private GP (2/3), government clinics (1/3) Despite poor involvement of GPs~3% Mandatory training for methadone, buprenorphine (not for other opioids!) Based on supervised dosing of most doses (methadone or buprenorphine)

Growth in treatment - GPs






Introduced after methadone, buprenorphine implemented 2 key issues **Benefits for patients** Unsupervised dosing 2. Concerns with injecting buprenorphine Despite supervised dosing


Bell 2007

Unsupervised dosing as effective as supervised Reduced heroin use 20 days less/month Unsupervised treatment less expensive ✓ ~ €300 (3/12), 30% reduction

Retention - identical



Uptake of Suboxone



Issues for patients

Having a choice of medications important Concern regarding naloxone in medication Had very limited access to take away doses – very interested in unsupervised dosing

Issues for prescribers

 Concern regarding injecting of buprenorphine
 Prescribers & pharmacists

 shift to Suboxone


 Very little use of non supervised dosing

 Policy and practice issues


Injecting opiates in Australia

Illicit Drug Reporting system Sentinel survey of drug injecting in Australia N~1000 IDU


IDRS – last drug injected



Injection – last 6 months



Buprenorphine injecting




Degenhardt 2009

Injecting buprenorphine Fra & Aus

		%	n
		injecting	
Roux 2008	France	32	111
Obadia 2001	France	24	343
Aitken 2008	Australia	32	316
Jenkinson 2005	Australia	33	156
Degenhardt 2009	Australia	23	513
		30	399

BPX waiting list study

Newcastle
 Lack of methadone & buprenorphine
 Long waiting lists
 6 months or longer



Outcome measures

Heroin use
Other drug use
Psychosocial state, quality of life, crime
Costs of treatment vs no treatment



✓ Adrian.Dunlop@hnehealth.nsw.gov.au